A Study of Guselkumab in Participants With Systemic Sclerosis

Summary

The purpose of the study is to evaluate the efficacy of guselkumab in participants with systemic sclerosis (SSc).

Timeline

Start

2021-02-24

Primary completion

2023-05-17

Completion

2024-07-09

Outcome

Met primary endpoint

registry Group A: Guselkumab vs Main Study: Group B: Placebo; p < 0.001; LS Mean Difference -12.6 (80% CI -13.8 to -11.4) NCT04683029 ↗

Drugs

Indications